Frankfurt, Germany - Soluble CD40 ligand can be used to identify ACS patients at highest risk for cardiac events and those who will receive most benefit from the GP IIb/IIIa blocker abciximab, a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback